Drug class
Low-molecular-weight heparin (LMWH); indirect anticoagulant
Mechanism of action
Binds antithrombin and potentiates its inhibition of activated factor Xa, with a smaller effect on thrombin (factor IIa), thereby reducing thrombin generation and fibrin clot formation.
General use cases
- Prevention of venous thromboembolic events in patients undergoing selected surgical procedures or immobilisation, according to local product authorisation
- Treatment of established deep-vein thrombosis in selected jurisdictions and formulations; dose and duration are product-specific
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
